

IBD Glossary and Reference Citations

Glossary

5-ASA:	5-aminosalicylic acid	JAK:	Janus kinase
ACIP:	Advisory Committee on Immunization Practices	mos:	months
AEs:	adverse events	PA:	prior authorization
AGA:	American Gastroenterological Association	Plt:	platelet
Alb:	albumin	PRN:	pro re nata (as needed)
ASCRS:	American Society of Colon and Rectal Surgeons	pts:	patients
BM:	bowel movement	Q2W:	every other week
CDC:	Centers for Disease Control and Prevention	Q8W:	every 8 weeks
C. diff:	<i>Clostridium difficile</i>	QW:	every week
CMV:	cytomegalovirus	sx(s):	symptom(s)
CRC:	colorectal cancer	TB:	tuberculosis
CRP:	C-reactive protein	TDM:	therapeutic drug monitoring
dx:	diagnosis	TI:	terminal ileum
GI:	gastrointestinal	TNF:	tumor necrosis factor
Hb:	hemoglobin	TPN:	total parenteral nutrition
hx:	history	tx:	treatment
IBD:	inflammatory bowel disease	UC:	ulcerative colitis
		wks:	weeks
		w/o:	without
		WBC:	white blood cell count

Therapies Mentioned in This Activity

Adalimumab:	Tumor necrosis factor inhibitor for subcutaneous use. Indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. Prescribing Information
Ciprofloxacin:	Fluoroquinolone antibacterial available in oral and injectable/intravenous formulations. Used for bacterial infections in a wide variety of diseases. Additional Information
Golimumab:	Tumor necrosis factor inhibitor for subcutaneous use. Indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Prescribing Information
Prednisone:	Corticosteroid/immunosuppressant available in oral and injectable/intravenous formulations. Used for inflammation in a wide variety of diseases. Additional Information
Tofacitinib:	Janus kinase inhibitor for oral use. Indicated for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Prescribing Information
Vancomycin:	Glycopeptide antibiotic available in oral and injectable/intravenous formulations. Used for gram-positive bacterial infections. Additional Information
Vedolizumab:	Integrin receptor agonist for intravenous use. Indicated for Crohn's disease and ulcerative colitis. Prescribing Information

IBD Glossary and Reference Citations

References

1. Vu M, Hommes DW. Step-Up Versus Top-Down Therapy in Ulcerative Colitis. In: Lichtenstein G, ed. *Medical Therapy of Ulcerative Colitis*. New York, NY: Springer Science+Business 2014;457-467.
2. Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. *Med Clin North Am*. 2010;94:1-18.
3. Dassopoulos T, Cohen RD, Scherl EJ, et al. Ulcerative colitis care pathway. *Gastroenterology*. 2015;149:238-245.
4. Ciriaco M, Ventrice P, Russo G, et al. Corticosteroid-related central nervous system side effects. *J Pharmacol Pharmacother*. 2013;4:S94-S98.
5. Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. *Gastroenterology*. 2017;153:827-834.
6. Zittan E, Kabakchiev B, Milgrom R, et al. Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn's Disease. *J Crohns Colitis*. 2016;10:510-515.
7. Papamichael K, Cheifetz AS. Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn's disease. *J Crohns Colitis*. 2016;10:507-509.
8. Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF- α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol*. 2016;14:550-557.
9. Prescribing information. Adalimumab (Humira®) injection for subcutaneous use. Revised October 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s4091bl.pdf. Accessed November 14, 2018.
10. Sofia MA, Rubin DT. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. *Therap Adv Gastroenterol*. 2016;9:548-559.
11. Roblin X, Vérot C, Paul S, et al. Is the pharmacokinetic profile of a first anti-TNF predictive of the clinical outcome and pharmacokinetics of a second anti-TNF? *Inflamm Bowel Dis*. 2018;24:2078-2085.
12. Afif W, Loftus EV, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. *Am J Gastroenterol*. 2010;105:1133-1139.
13. Dalal SR, Cohen RD. What to do when biologic agents are not working in inflammatory bowel disease patients. *Gastroenterol Hepatol*. 2015;11:657-665.
14. Ross H, Steele SR, Varma M, et al. Practice parameters for the surgical treatment of ulcerative colitis. *Dis Colon Rectum*. 2014;57:5-22.
15. Mantzaris GJ, Petraki K, Archavlis E, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. *Scand J Gastroenterol*. 2001;36:971-974.
16. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. *Gut*. 1986;27:1210-1212.
17. Dickinson RJ, O'Connor HJ, Pinder I, et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. *Gut*. 1985;26:1380-1384.
18. Mantzaris GJ, Hatzis A, Kontogiannis P, et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. *Am J Gastroenterol*. 1994;89:43-46.
19. McIntyre PB, Powell-Tuck J, Wood SR, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. *Gut*. 1986;27:481-485.
20. Dickinson RJ, Ashton MG, Axon AT, et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. *Gastroenterology*. 1980;79:1199-1204.
21. Prescribing information. Vedolizumab (Entyvio®) injection for intravenous use. Revised February 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125476s0221bl.pdf. Accessed November 14, 2018.
22. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*. 2013;369:699-710.
23. Cherry LN, Yunker NS, Lambert ER, et al. Vedolizumab: an $\alpha 4\beta 7$ integrin antagonist for ulcerative colitis and Crohn's disease. *Ther Adv Chronic Dis*. 2015;6:224-233.
24. Prescribing information. Tofacitinib (Xeljanz®) tablets for oral use. Revised October 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203214s020,208246s0061bl.pdf. Accessed November 14, 2018.
25. Caldera F, Lasch K, Cao C, et al. P051 Lower incidence of herpes zoster in vedolizumab-treated vs. tofacitinib-treated patients with ulcerative colitis. *J Crohns Colitis*. 2018;12(1 suppl):S117-S118.
26. Winthrop KL, Melmed GY, Vermiere S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. *Inflamm Bowel Dis*. 2018;24(10):2258-2265.